________________________________________________________________________________________________________________________________

(C) Wolf G Kroner 2012 - Peter Durkee MeldrumThe Myriad Way

March 2012. Myriad Genetics’ offerings are contentious, in particularly when it comes to patent protection of genes. Once in Europe, today in the U.S. scientific societies or NGOs attack the company and its services. In the exclusive interview with B2Bioworld, Peter Meldrum, CEO and co-founder of the Utah-based company describes expansion plans with biomarker services. He takes a stand on clinical DNA chips, and answers reproaches of patenting human genes, blocking scientific research, or pursuing a strangling licence policy for those laboratories willing to make breast cancer or colon carcinoma tests more widely available to patients.

July 2015. After more than 24 years Mr. Meldrum retired June 30, 2015. However he continues to have his say in the company as non-employed consultant, and the issues talked about in the interview are still shaping hhis company's path forward. Accroding to B2Bioworld's information Mr.. Meldrum also continues in a US venture capital company. ed.

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 6 pages

Full Company License enquire here

Back to section

Related Editorial Articles

Transition Cancer Research Translation
Christof von Kalle, Head of National Center for Tumor Diseases at Heidelberg

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, former Chief Technology Officer Life Sciences at Tecan on strengths and weaknesses of electrowetting development, weaknesses of competitors like Illumina. Prospects of clinical microfluidics

Patient-centered Precision Care
Michael Christman, President of Coriell Institute on turning research on human genotyping into healthcare routine and attracting payors

Metrics for Disease, Health, and Wellness
'A systems look at DNA sequencing for personalized medicine by Leroy Hood, President Institute for Systems Biology, Seattle

Teeth to the Convention on Biological Diversity
Christian Wichard, Deputy Director General of WIPO on its role in enforcing compliance with access and benefit sharing requirements

Improving the IP System on a global scale: A view from Japan
Sadao Nagaoka, Institute of Innovation Research, and Chief Policy Adviser to the Japanese Government

Is that worth a dollar, or a million dollars?
Ed Torres, Managing Director of Lilly Ventures on the Fund’s input to Eli Lilly’s business development

Systems Biology Applied
The Need of Systems Theory Thinking in Using Technologies and Pitfalls of Some Concepts

Custom Sequencing Markets
Worldwide evolution of the market and upcoming business opportunities. B2Bioworld asked Bruno Poddevin, Eurofins Genomics Services

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – reflecting on personalised medicine

Patenting Stem Cells – Behind the Front Stage
The patentability of stem cells is of continuing debate. The article outlines the legal approach to stem cells as it informs solving juridical problems

Bayer AG: New Stakes in Stem Cells
Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global